Acadia Pharmaceuticals (ACAD)

Company Description

ACADIA Pharmaceuticals (ACAD) focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead drug candidate is NUPLAZID, which has delivered positive data in Phase III pivotal trials with a pristine safety profile for the treatment of Parkinson’s disease psychosis, an unmet medical need.   The potential blockbuster is also in Phase II development for Alzheimer’s disease psychosis and is currently planning a Phase II trial for the treatment of schizophrenia. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc.

 

COMPANY ADDRESS
3611 Valley Centre Drive; Suite 300
San Diego, CA 92130
United States

COMPANY PHONE
(858) 558-2871

COMPANY WEBSITE


Get BioInvest's perspective on Acadia's CEO

Latest Company News

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock ABR At 1.67 Stock Observer - 6 hours ago After closing a study on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), the advisors gave it stock target of $43.666. This estimation is outcome of Zacks survey, which contained 9 experts. [...]
Fri, Mar 24, 2017 6:56:00 PM, Continue reading at the source
ACADIA Pharmaceuticals Inc. (ACAD) Lifted to Hold at Zacks Investment Research The Cerbat Gem - 9 hours ago ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - Midway Monitor ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Selling Update - Melville Review [...]
Fri, Mar 24, 2017 4:30:00 PM, Continue reading at the source
Is It Time to go for ACADIA Pharmaceuticals Inc. (ACAD), AvalonBay Communities ... StockNewsJournal - 13 hours ago ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. [...]
Fri, Mar 24, 2017 12:33:00 PM, Continue reading at the source
The Technical Chart For ACADIA Pharmaceuticals Inc. (ACAD) Has Spoken NY Stock News - Mar 23, 2017 ACADIA Pharmaceuticals Inc. (ACAD) has created a compelling message for traders in the most recent trading. That message has grown stronger as the technical chart setup has developed into a more composite picture for the stock. [...]
Thu, Mar 23, 2017 4:52:00 PM, Continue reading at the source
Analyst's Predictions on ACADIA Pharmaceuticals Inc. (ACAD), Santander ... StockNewsJournal - Mar 20, 2017 ACADIA Pharmaceuticals Inc. (ACAD) have shown a high EPS growth of -40.00% in the last 5 years and has earnings decline of -43.30% yoy. [...]
Mon, Mar 20, 2017 12:56:00 PM, Continue reading at the source
Don't Be So Sure ACADIA Wants To Sell Seeking Alpha - Mar 7, 2017 I have owned for myself and the Clients of Mott Capital Management, LLC shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) for well over two years now. ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Has A Problem With Nuplazid - BNL Finance (press release) (registration) (blog) ACADIA Pharmaceuticals Inc. (ACAD): What's the Story? - StockNewsJournal [...]
Tue, Mar 07, 2017 1:00:00 PM, Continue reading at the source
ACADIA: A Buyout Remains Most Likely Scenario Seeking Alpha - Mar 3, 2017 ACADIA Pharmaceuticals has surged ahead some 80% over the past year thanks to the FDA approval of Nuplazid, the first drug to be approved for the psychosis associated with Parkinsons. [...]
Fri, Mar 03, 2017 6:33:00 PM, Continue reading at the source
Earnings Reaction History: ACADIA Pharmaceuticals Inc, 50.0% Follow-Through ... Nasdaq - Feb 28, 2017 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement ... [...]
Tue, Feb 28, 2017 7:41:00 PM, Continue reading at the source
ACADIA Pharma Looks Like A Take-Out Target Seeking Alpha - Feb 27, 2017 But one company in particular has this San Diegan very interested. The company I'm talking about is ACADIA Pharmaceuticals (NASDAQ:ACAD), and in a field of speculative, pre-FDA-approval pharma companies, ACADIA has potential few others possess. [...]
Mon, Feb 27, 2017 7:41:00 PM, Continue reading at the source
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time? Yahoo Finance - Feb 23, 2017 The company's track record is dismal. ACADIA has missed estimates in all the trailing four quarters, bringing the average negative earnings surprise to 19.07%. [...]
Thu, Feb 23, 2017 9:54:00 PM, Continue reading at the source